Quick Answer: GHRP-2, GHRP-6, hexarelin, and ipamorelin are all synthetic GHS-R1a agonists that stimulate pulsatile growth hormone secretion, but they differ substantially in potency, receptor selectivity, cortisol co-stimulation, and secondary tissue effects differences that determine which compound researchers select for a given model
This is the foundation for the oral route argument
The approved regimen is a 1.75 mg dose , across the board and not based on weight
This reasoning is also supported by the fact that another animal species, the dog, is not affected by the compound at similar or higher doses
Complementary peptide combinations Several peptide categories combine logically with MOTS-c based on complementary mechanisms